Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
95
resultados
Última actualización
02/11/2026 [09:01:00]
Resultados 25 a 50 de 95
Resumen de: WO2026220159A1
Pharmaceutical compositions of colchicine for once-daily oral administration are provided for use in the treatment of chronic inflammation, including inflammation arising after COVID-19 vaccination and/or COVID-19 infection (Long COVID). The formulations comprise, in some embodiments, an immediate-release component and/or a sustained-release component, which is tailored to achieve a desired pharmacokinetic profile suitable for long-term anti-inflammatory therapy. The disclosed compositions are designed to reduce systemic levels of key inflammatory biomarkers, such as high-sensitivity C-reactive protein (hs-CRP), C-reactive protein (CRP), interleukin-1 (IL-1), interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and myeloperoxidase (MPO), and to alleviate clinical manifestations of persistent inflammation, including vaccine-associated myocarditis, pericarditis, or other inflammatory sequelae. Methods of treating post-vaccination and/or post-infection inflammatory syndromes, improving quality of life, and reducing hospitalization risk in mammalian subjects are also provided.
Resumen de: WO2026222182A1
Disclosed herein is a library of SARS-CoV-2 PLpro inhibitors. The compounds described herein represent potent inhibitors of PLpro with activity translating to live virus assays in mammalian and human host cells. Also provided herein are methods of using the PLpro inhibitors for preventing or treating infections, diseases, and/or symptoms caused by exposure to a coronavirus, such as SARS-CoV-2, SARS-CoV-1, and MERS in a subject in need thereof.
Resumen de: WO2022171304A1
A probiotic composition comprising Lactobacillus plantarum CECT 30292, Lactobacillus plantarum CECT 7484, Lactobacillus plantarum CECT 7485, and Pediococcus acidilactici CECT 7483 is provided. The probiotic composition is useful in treating, preventing, or ameliorating COVID-19 or symptoms, complications and/or sequela thereof, and other infectious diseases. It is also useful in enhancing the immune response.
Resumen de: US20260325553A1
0000 Methods and compositions to lessen toxicities in COV19 vaccine aftermath. These involve administering synergistic or complementary formulations of early detoxification agents, antioxidants, anti-inflammatories, pro-immunity agents, gp41/gp120 inhibitors, nAChR/NAD<+>, boosters, ACE-2 modulators, anticoagulants and other micronutrients, vitamins, plant-derived compounds and selections from pertinent, major drug classes. tailored to address post-vaccination complications effectively.
Resumen de: EP4825448A2
0001 Provided herein are methods of treating or preventing SARS-CoV-2 infection comprising modulating interactions between the SARS-CoV-2 spike protein and plasma membrane-expressed host cell proteins, as well as methods of identifying modulators of such interactions.
Resumen de: PL451832A1
Przedmiotem zgłoszenia jest elektroda czujnikowa do zastosowania w diagnostyce bioelektrochemicznej koronawirusa SARS-CoV-2, która charakteryzuje się tym, że stanowi podłoże krzemowe z naniesioną warstwą diamentu domieszkowanego borem (BDD), która zbudowana jest z polidopaminy PDA i polizwitterjonu PZ z receptorami ACE2 zakotwiczonymi na powierzchni BDD za pomocą oddziaływań niekowalencyjnych elektrostatycznych i dyspersyjnych wytworzonych między merami dopaminy, polizwitterjonu i ACE-2 a podłożem BDD w trakcie procesu elektropolimeryzacji, przy czym ACE-2 jest doczepiony do powierzchni elektrody i jest związany za pomocą polimerów PDA-PZ. Przedmiotem zgłoszenia jest także sposób otrzymywania elektrody czujnikowej do zastosowania w diagnostyce bioelektrochemicznej koronawirusa SARS-COV-2 oraz sposób detekcji bioelektrochemicznej koronawirusa SARS-COV-2.
Resumen de: US20260317820A1
0000 Aspects of the present disclosure are directed to methods and systems for sample collection, tRNA sequencing, and diagnosis, prognosis, and treatment of viral infections such as SARS-CoV-2. Disclosed herein are methods for tRNA sequencing and analysis, including obtaining a tRNA profile of RNA from a nasopharyngeal sample. A tRNA profile may include abundance, fragmentation, and/or modification information for a plurality of tRNAs from a sample. Also disclosed are methods for diagnosis, prognosis, and/or treatment of a viral infection (e.g., SARS-CoV-2 infection) based on abundance, fragmentation, and/or modification information for one or more tRNAs from a subject having or suspected of having a viral infection.
Resumen de: US20260315510A1
Problem The present invention has as an object to provide an antiviral agent effective as a remedy for COVID-19 and other viral infections.Resolution Means Provided is an antiviral agent and the like, made of: the compound represented by general formula (1) or (2) below R1 being —(CH2)n1-Z1—R11 or —CH—(—Z1—R11)2 (n1 being 0 or 1; Z1 being a single bond, —O—, —NH—, —S—, —SO—, —SO2—, —CO—, —CO—O—, or —CH═N—O—; R11 being a hydrogen atom, an alkyl group having 1 to 6 carbons, —NR12R13, —N3, —NO2, —CN, —CH2—CO—O—R14, or a five- or six-membered heterocyclic group including a nitrogen atom; R12 and R13 each independently being a hydrogen atom or an alkyl group having 1 to 6 carbons; and R14 being a hydrogen atom or an alkyl group having 1 to 6 carbons, a derivative thereof, a salt of these compounds, or a solvate thereof.
Resumen de: US20260315522A1
The present disclosure relates to improving oral-nasal health by increasing, oral, intraoral and nasal cavity nitric oxide levels using a novel prebiotic nitrate-formulated chewing gum composition, together with an optional step comprising the use of saliva test strip to monitor pH, nitrate, and nitrite. The novel gum compositions and methods of the invention result in improved nitric oxide bioavailability and thereby increase antimicrobial nitric oxide levels beneficial for reducing dental caries, periodontitis, and nasopharyngitis, as well as reduce transmission of aerosolized viral particles acutely sensitive to nitric oxide, including SARS-COV.
Resumen de: US20260317403A1
0000 Antibodies, including single-domain antibodies, that bind to SARS-CoV2 virus and methods of treatment using single-domain antibodies that bind to SARS-CoV2 virus are provided.
Resumen de: US20260315714A1
0000 Provided are products of manufacture fabricated or manufactured as medical devices such as an inhaler, an ionizer, an asthma “puffer-like” device, a nebulizer or a nasal spray device, a respirator or a ventilator, a warm or a hot air delivery device, and/or a CPAP (continuous positive air pressure) device (for example, for managing or treating sleep apnea) or equivalent, for delivering one or a combination of medications or drugs, and optionally also warm or hot air, and optionally also ionized air. Products of manufacture are used for treating, preventing, ameliorating, slowing the progress of, decreasing the severity of or preventing a microbial infection, such as bacterial and viral infections, including the common respiratory viruses such as influenza virus, respiratory syncytial virus, picornavirus, parainfluenza virus, adenovirus, rhinovirus, human metapneumovirus, hantaviruses, enterovirus, a coronavirus infection, or a COVID-19 or a 2019-nCoV (or so-called Wuhan coronavirus) infection.
Resumen de: WO2026215512A1
The present disclosure relates to methods of immunizing individuals for prophylaxis or prevention of an infection by a virus (e.g., a sarbecoronavirus virus such as a SARS-CoV-2 virus) and methods of inducing a pan-variant immune responses against a virus using low doses of vaccines.
Resumen de: US20260315560A1
Provided is use of Shenling Baizhu in preparing a medicament for treating post-healing sequelae of a novel coronavirus infected person. The sequela is selected from at least one of shortness of breath, fatigue and weakness, inappetence, and diarrhea. The Shenling Baizhu is prepared from the following raw materials in parts by weight: 400 parts of ginseng, 400 parts of Poria cocos, 400 parts of Rhizoma Atractylodis macrocephalae stir-fried with bran, 400 parts of Chinese yam, 300 parts of fried white hyacinth beans, 200 parts of lotus seeds, 200 parts of coix seeds stir-fried with bran, 200 parts of Fructus amomi, 200 parts of Platycodon grandiflorum, and 400 parts of liquorice.
Resumen de: US10815539B1
The present invention is directed to methods for assaying for the presence of SARS-CoV-2 in a sample, including a clinical sample, and to oligonucleotides, reagents and kits useful in such assays. In particular, the present invention is directed to such assays that are rapid, accurate and specific for the detection of SARS-CoV-2.
Resumen de: WO2023161837A1
The invention concerns a microwave disinfection device ( 2 ) configured to destroy/ inactivate the SARS-CoV-2 and H1N1 viruses and comprising a microwave irradiation section ( 22 ) configured to : irradiate microwave signals that have an incident electric field amplitude not higher than 6 V/m and frequencies that are included in the 8-10 GHz band and are spaced from each other by a step comprised between 10 MHz and 100 MHz; irradiate the microwave signals at each individual frequency for a time interval comprised between 50 ms and 1 s; and irradiate the microwave signals with duty cycles comprised between 5% and 50%.
Resumen de: US20260306577A1
0000 The invention relates, inter alia, to methods of preparing a garlic oil, garlic oils produced using the method, pharmaceutical compositions comprising the garlic oil and uses of the garlic oil in the treatment of viral infections such as SARS-COV-2 and influenza A. The methods of preparing a garlic oil comprise the steps of: a) processing a portion of a garlic plant to increase its surface area; b) ageing the portion of the garlic plant for at least 18 months to provide an aged garlic, which does not comprise addition of ethanol; and c) separating the garlic oil in the aged garlic. Step c) may be performed using spinning cone distillation or supercritical fluid extraction, at a temperature below 110° C., or such that the pressure (atmospheres) divided by the temperature (degrees Kelvin) is equal to or less than about 0.0026.
Resumen de: WO2026213490A1
Described herein is a novel bat influenza A virus-based vaccine vector modified by replacing the open reading frame of either bat influenza hemagglutinin or neuraminidase with that of hemagglutinin-esterase-fusion gene from influenza D virus that can infect multiple species including humans and camels. A temperature-sensitive, cold-adapted and attenuated MERS vaccine candidate expressing the clade A MERS-CoV spike S1 was then developed, referred to as Len_S1, using the developed bat influenza vector and demonstrated its safety and immunogenicity. A single-dose intranasal immunization with Len_S1 was able to protect hDPP4 transgenic mice from a lethal MERS-CoV challenge. Notably, two-dose immunization with Len_S1 completely blocked viral replication and lung damage of challenged mice. Len_S1 is a safe and effective MERS vaccine that can induce a comprehensive immune response and provide cross-protection against different clades of MERS-CoVs.
Resumen de: WO2026213157A1
The present disclosure relates to methods of treating coronavirus disease 2019 (COVID-19), methods of assessing risk(s) associated with COVID-19, and methods of preventing long COVID.
Resumen de: US20260305587A1
The present invention discloses a humanized ACE2-expressing transgenic mouse, which is susceptible to infection by the SARS-CoV-2 virus, obtained through the application of the CRISPR system, and a method for producing the same. The humanized ACE2-expressing transgenic mouse of the present invention reflects symptom severity and mortality patterns according to age, sex, and viral inoculation dose, as observed in human COVID-19 cases, and reproduces the immunopathological characteristics of SARS-CoV-2 infection in the lungs without viral replication or lesions in the brain. Therefore, it can be usefully employed for understanding the pathogenic mechanisms of SARS-CoV-2 and for the development of vaccines or therapeutics.
Resumen de: US20260309709A1
An improved assay to measure immunogenicity of vaccines while overcoming some of the limitations of current biomarkers of immunogenicity is necessary. Disclosed herein is an assay for measuring inhibition of binding between SARS-CoV-2 Spike (S) glycoproteins and hACE2. Also provided herein are methods of using the assay to evaluate the efficacy of COVID-19 vaccines.
Resumen de: UA131281C2
The present invention provides methods for preventing and treating SARS-CoV-2 infections, COVID-19, or symptoms thereof. The methods of the invention feature the administration of one or more antigen-binding molecules (e.g., antibodies) that bind a surface protein of SARS-CoV-2 (e.g., spike protein).
Resumen de: EP4817612A2
0001 Provided is application of a poly ADP ribose polymerase inhibitor or a pharmaceutically acceptable salt thereof in the preparation of antiviral agents or in the preparation of medicines for the treatment of diseases caused by viruses, wherein the viruses are β-coronavirus viruses. Also provided is application of a compound represented by formula III and/or a compound represented by formula IV or a pharmaceutically acceptable salt thereof in the preparation of antiviral agents or in the preparation of medicines for treatment of diseases caused by viruses, the viruses being HIV, HPV, EBV, IFV and/or coronaviruses. The poly ADP ribose polymerase inhibitor comprises a compound represented by formula III and/or a compound represented by formula IV or a pharmaceutically acceptable salt thereof, and can achieve a lower effective concentration for inhibiting viruses and a higher antiviral activity while ensuring low toxicity and high safety when being used in human bodies, so that in the application to the clinical treatment of diseases caused by coronaviruses, the present inhibitor can effectively inhibiting the viruses.
Resumen de: EP4818164A1
0001 The present invention relates to an indole derivative of formula (I)
3,3'-(pyridine-3,5-diylbis(5-methoxy-1H-indole-2,1-diyl))bis(N,N-dimethylpropan-1-amine) as inhibitors of interaction between Spike and ACE2 proteins for the treatment of infections due to respiratory viruses, such as e.g. SARS-CoV-1, SARS-CoV-2 or MERS CoV infections.
Resumen de: MX2025003049A
The present invention relates generally to the identification and/or detection of certain substances present in the sweat of a subject, including emitted and detectable substances present in the sweat of a subject, more particularly in the present invention are identified volatile organic compounds or molecules (VOCs) that are organic molecules, that are secreted distinctive or only in subjects curing by an infectious process, and more particularly in a COVID -19. Infection. In this way, a volatiloma or pseudo-aromas generated from such volatile organic sweat VOC compounds is created and are useful for diagnosing people infected with SARS-COV-2 and also for canine training in the detection of people with SARS-COV-2 (COVID -19) with projections to other infectious diseases.
Nº publicación: WO2026207328A1 01/10/2026
Solicitante:
PURDUE RES FOUNDATION [IN]
ALHASHIMI MARWA [US]
PURDUE RESEARCH FOUNDATION
ALHASHIMI, Marwa
Resumen de: WO2026207328A1
A combined multi-antigen utilizing an immunogenic vector expressing a modified SARS-CoV-2 virus S, M and N protein S-C5 (Delta or Omicron), M-C5, and N-C5, epitopes thereof, compositions comprising same, and methods of use for general vaccination against SARS-CoV-2 virus.
BOPI
Sede Electrónica
